CapsoVision (CV) Cash from Financing Activities (2024 - 2025)

CapsoVision (CV) reported Cash from Financing Activities of $15000.0 for Q4 2025, down 99.7% on a YoY basis from $5.0 million in Q4 2024, and down 99.93% sequentially from $22.4 million in Q3 2025.

CapsoVision (CV) Cash from Financing Activities (2024 - 2025) Analysis & Trends

CapsoVision (CV) has 2 years of Cash from Financing Activities data on file, last reported at $15000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 99.7% year-over-year to $15000.0; the trailing twelve-month figure through Dec 2025 stood at $37.4 million (changed N/A YoY), and the FY2025 full-year result was $23.6 million, up 56.59% from the prior year.
  • Cash from Financing Activities slipped to $15000.0 in Q4 2025, from $22.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $22.4 million in Q3 2025 to a low of $15000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 17.31 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -1.51 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn -888.00 Mn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -260.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn -451.20 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -25.00 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn -26.93 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 21.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 CapsoVision 162.07 Mn 151.95 Mn 1.95 Mn 15,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 15,000.00
Dec 31, 2025 15,000.00
Sep 30, 2025 22.39 Mn
Sep 30, 2025 22.39 Mn
Dec 31, 2024 5.00 Mn
Dec 31, 2024 5.00 Mn
Sep 30, 2024 10.00 Mn
Sep 30, 2024 10.00 Mn